[company_age]10.0[/company_age][employees]11-50 employees[/employees][funding]Series C[/funding][description]XENOTHERA is a clinical-stage biotechnology company specializing in the development of First-In-Class drugs primarily for oncology and hematology. Their disruptive immunotherapy, based on a patented platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb), addresses significant unmet medical needs, particularly in solid and liquid tumors. The company's accelerated development is facilitated by its scaled-up commercial-grade industry, regulatory and clinical expertise, and in-house bioproduction facility.\n\nWhat sets XENOTHERA apart is its commitment to:\n\n* **Innovation:** Their proprietary GH-pAb platform enables the development of highly effective and well-tolerated treatments with a broad range of therapeutic applications.\n* **Responsiveness:** They prioritize rapid development and delivery of treatments to patients in need, particularly for emerging or neglected pathologies.\n* **Agility:** Their competent and adaptable team, coupled with their robust technological platform, allows them to respond swiftly to diverse medical challenges.\n* **Social Responsibility:** They demonstrate a strong commitment to environmental sustainability, animal welfare, and patient well-being through their adherence to the 3R principle and ethical research practices.\n\nXENOTHERA's dedication to these values positions them as a leader in the biotechnology industry, driving advancements in patient care and shaping the future of medicine.[/description][ps]Glyco-humanized polyclonal antibodies for the treatment of various diseases, including cancer and infectious diseases.[/ps]